Aktis Oncology, Inc. AKTS
Set alert
14.59 USD -1.34 -8.41%
At close
14.71 +0.12 +0.83%
Pre-market · Nov 3, 6:32 AM ET
13.96 Day range 16.01
13.96 52-week range 34.19
- YTD
- -34.87%
- 1 year
- -34.87%
- Open
- 16.01
- Prev close
- 15.93
- Mkt cap
- 811.49M
- Vol
- 898.18K
- Avg vol
- 361.49K
- EPS
- -1.70
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.96
- High
- 16.01
- Forward P/E
- -8.45
- Beta
- 0.00
- Short ratio
- 10.89
- Inst. own
- 73.01%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 22.96
- 200-d avg
- 21.42
- 1y target
- 35.39
MAX chart
Events in this range
- Mar 30, 2026Earnings: -18.19; estimate -21.59333; surprise 15.76%
- May 11, 2026Earnings: -0.38; estimate -0.31; surprise -22.58%
- Jun 16, 2026Rating: Raymond James · — → Strong Buy
- Jul 14, 2026Rating: JP Morgan · Overweight → Overweight
- Aug 13, 2026Earnings: -0.44; estimate -0.43065; surprise -2.17%
- Aug 19, 2026Rating: BMO Capital · — → Outperform
- Aug 19, 2026Rating: Wedbush · — → Outperform
- Sep 9, 2026Rating: Oppenheimer · — → Outperform
- Oct 2, 2026Rating: Wedbush · Outperform → Outperform
Signals (69)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 3 days ago |
| SMA: Bullish | Oct 27, 2026 | 6 days ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 22, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Sep 30, 2026 | 1 month ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Jul 16, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 8, 2026 | 3 months ago |
| SMA: Bearish | Jul 6, 2026 | 3 months ago |
Newest 20 of 69.
Financial health
Altman Z-Score
6.57 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 2
Valuation
P/E -18.8×
FY 2022 5y median -23.1× FY 2025
P/S 181×
FY 2022 5y median 90.5× FY 2025
P/B -8.0×
FY 2022 5y median -12.9× FY 2025
P/FCF -16.0×
FY 2022 5y median -19.5× FY 2025
EV/EBITDA -18.7×
FY 2022 5y median -23.3× FY 2025
EV/Sales 177×
FY 2022 5y median 88.5× FY 2025
FCF Yield -6.3%
FY 2022 5y median -3.5% FY 2025
Profitability
Gross Margin 100.0%
FY 2022 5y median 50.0% FY 2025
Operating Margin -1149.5%
FY 2022 5y median -574.8% FY 2025
Net Margin -980.9%
FY 2022 5y median -490.5% FY 2025
ROE 43.6%
FY 2022 5y median 56.0% FY 2025
ROIC -31.8%
FY 2022 5y median -23.2% FY 2025
ROA -24.1%
FY 2022 5y median -18.4% FY 2025
Growth (YoY)
Revenue 336.9%
FY 2022 FY 2025
Operating Income -43.5%
FY 2022 FY 2025
EPS (diluted) 5.6%
FY 2022 FY 2025
Free Cash Flow -719.4%
FY 2022 FY 2025
Financial Health
Current Ratio 7.4×
FY 2022 5y median 16.0× FY 2025
Quick Ratio 7.4×
FY 2022 5y median 16.0× FY 2025
Debt / Equity -0.1×
FY 2022 5y median -0.1× FY 2025
Net Debt / EBITDA 0.4×
FY 2022 5y median 0.6× FY 2025
Interest Coverage 0.0×
FY 2022 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2022 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2022 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31